Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.
Renke
Marcin
M
Knap
Narcyz
N
Tylicki
Leszek
L
Rutkowski
Przemyslaw
P
Neuwelt
Alexander
A
Larczynski
Wojciech
W
Wozniak
Michal
M
Rutkowski
Boleslaw
B
D000328:Adult; D000069059:Atorvastatin; D015237:Dinoprost / Q000031:analogs & derivatives; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D028421:Isoprostanes / Q000652:urine; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000652:urine; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D010919:Placebos; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D028421:Isoprostanes; D010919:Placebos; D011758:Pyrroles; C075750:8-epi-prostaglandin F2alpha; D000069059:Atorvastatin; D015237:Dinoprost